Compared to the control group, treatments with RSL3, Erastin and Ibrutinib effectively reduced the tumor sizes (Fig. 6A, B) with decreased expression levels of GPX4, SOD1 and CAT (Fig. 6C). This evidence concerns the gene CAT and neoplasm.